Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Gubra
650
DKK
+5,52 %
GUBRA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Alle 1K seuraajaa
+5,52%
+1,56%
+4,17%
+0,93%
+19,49%
+318,01%
-
-
+490,91%
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Lue lisääMarkkina-arvo
10,63 mrd. DKK
Vaihto
21,56 milj. DKK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Seuranta
Viimeisimmät analyysit
Viimeisin analyysiraportti
Julkaistu: 09.09.2024
Pörssikalenteri
28.2.
2025
Vuosikatsaus '24
NäytäKaikki sisältötyypit
Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist
Gubra announces positive GUBamy Phase 1 SAD data (correction)
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Gubra announces positive GUBamy Phase 1 SAD data

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Gubra – Presentation of Q3 2024

Gubra: Another strong quarter in CRO and pipeline update
Trading statement Q3-2024: Another strong quarter

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation
Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates
Major shareholder announcement

Gubra - Presentation of Q2 report 2024
Interim report H1 2024: Strong performance across Gubra
Gubra raises financial outlook for 2024
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
